In the field of a "red sea" of display screens, there is a potential for a "dark horse" to emerge. OLED (Organic Light Emitting Display), which has self luminous, thinner, and brighter characteristics, is being used by Apple in its mobile and watch products. Next, the application of OLED in various Apple product lines will be fully launched. Shanghai and Glow Electric are committed to this track and have achieved independent and controllable core technology. Currently, their shipment volume ranks first globally. "It is the industrial and financial fertile ground in Shanghai that helps us continue to carry out research and development innovation and technological breakthroughs," said Zou Zhongzhe, assistant to the general manager of Hehui Optoelectronics.
The display screen of
and Glow Optoelectronics can achieve both black and bright.
Technology and financial support, which are already inseparable resources, have achieved mutual achievement and perfect unity in Shanghai.
Recently, the "Pujiang Light" Towards Tomorrow's Science and Technology Innovation Star Summit, jointly hosted by the Shanghai Investment Promotion Service Center (Shanghai SME Listing Promotion Center) and the Lujiazui Management Bureau of the China (Shanghai) Pilot Free Trade Zone Management Committee, revealed the "cooperation achievements" of Shanghai's industry and finance. As of December 28 this year, 441 A-share listed companies in Shanghai have raised more than 500 billion yuan through initial public offerings, The proportion in the country is 8.3% and 10% respectively; In the five years since the establishment of the Science and Technology Innovation Board, there have been 89 listed companies on the board in Shanghai, ranking first in terms of initial fundraising and total market value in the country. Among these 89 listed companies, two-thirds involve Shanghai's leading industries such as integrated circuits and biopharmaceuticals, such as SMIC, Hehui Optoelectronics, and Maiwei Biotechnology, with significant demonstration effects in the sector. In addition, from the financing situation, in the first three quarters of this year, Shanghai had a total of 919 equity investment cases, with a financing amount of 117.2 billion yuan, ranking first in the country.
Maiwei Biotechnology has achieved rapid growth in Shanghai. Maiwei Biotechnology was established in May 2017 and was listed on the Science and Technology Innovation Board in January 2022. CEO Liu Datao did not forget to add, "Maiwei Biotechnology is just one of the four listed companies that have 'split' from Shanghai Junshi Biotechnology."
In fact, the current biopharmaceutical field is being seen by the industry as entering a "capital winter". But even so, Shanghai is still giving birth to miracles. Chen Kai, the head of AstraZeneca China International Life Sciences Park, said that this year marks AstraZeneca's 30th anniversary in China. AstraZeneca has established its headquarters in China and Asia Pacific in Zhangjiang, as well as its global R&D center in Jing'an District. But the most shocking event for him was that this year was the year when AstraZeneca invested the most in Chinese biopharmaceutical companies. "By the end of this year, there were a total of 7 transaction cases, with an average of one in less than two months. Two of these huge transactions were related to Shanghai."
It is reported that these two transaction cases are: in December this year, AstraZeneca acquired Shanghai based Genxi Biotechnology for $1.2 billion, thereby adding GC012F CAR-T cell therapy to AstraZeneca's continuously expanding cell therapy pipeline. After the acquisition is completed, Genxi Biotechnology will operate as a wholly-owned subsidiary of AstraZeneca in China and the United States. In November, Zhangjiang Enterprise Chengyi Biotechnology announced an exclusive licensing agreement with AstraZeneca. AstraZeneca will develop and commercialize the small molecule GLP-1 receptor agonist discovered by Chengyi Biology for potential treatment of obesity, type 2 diabetes and other complications. According to the terms of the agreement, Chengyi Biotechnology will receive a down payment of $185 million and will also be eligible for future clinical, registration, and commercialization milestone payments of up to $1.825 billion, as well as licensing fees.
Chen Kai believes that these two amazing moves mean that in the future, Shanghai, China may become an engine for global research and industrialization in areas such as innovative therapies and iterative cell therapy technologies.
Zhou Jingye, Founder and CEO of Chengyi Biotechnology.
"Industry starts with technology and becomes with finance." According to Wang Dong, director of the Shanghai Investment Promotion Service Center (Shanghai SME Listing Promotion Center), the development of Shanghai's industry, supported by technology and finance, stems from the "iceberg theory", which states that the tip of the ice above the water surface only accounts for 10% of the iceberg, which is an explicit part, while the vast 90% is hidden below the water surface. "The unique spirit of 'rules, order, and integrity' in Shanghai's Shanghai style culture is the underlying logic that drives the high-quality development of Shanghai's industries below the water surface."
Wang Dong, Director of Shanghai Investment Promotion Service Center (Shanghai SME Listing Promotion Center).
The main functions of the Shanghai Investment Promotion Service Center (Shanghai SME Listing Promotion Center) are to attract investment and cultivate listings. Wang Dong revealed that in terms of listing cultivation, the center is continuously maintaining and updating the "Shanghai Restructuring and Listing Cultivation Enterprise Database" to reserve resources for major stock exchanges. At present, the total number of inbound enterprises has reached 917, of which 121 have been listed through cultivation. Over the past 16 years, the center has trained more than 5000 entrepreneurs who plan to go public, and the domestic and foreign listed enterprises promoted by the center account for more than 70% of the city's listed enterprises.
